Ticker
AKBA

Price
0.40
Stock movement up
+0.01 (2.56%)
Company name
Akebia Ther
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
73.41M
Ent value
408.09M
Price/Sales
0.33
Price/Book
2.81
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-85.07%
3 year return
-54.30%
5 year return
-51.63%
10 year return
-
Last updated: 2022-08-25

DIVIDENDS

AKBA does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales0.33
Price to Book2.81
EV to Sales1.83

FINANCIALS

Per share

Loading...
Per share data
Current share count183.53M
EPS (TTM)-1.57
FCF per share (TTM)-1.16

Income statement

Loading...
Income statement data
Revenue (TTM)222.97M
Gross profit (TTM)72.84M
Operating income (TTM)-258.88M
Net income (TTM)-275.68M
EPS (TTM)-1.57
EPS (1y forward)-0.44

Margins

Loading...
Margins data
Gross margin (TTM)32.67%
Operating margin (TTM)-116.10%
Profit margin (TTM)-123.64%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash174.56M
Net receivables64.58M
Total current assets302.69M
Goodwill55.05M
Intangible assets99.12M
Property, plant and equipment0.00
Total assets535.36M
Accounts payable19.47M
Short/Current long term debt135.19M
Total current liabilities253.91M
Total liabilities509.24M
Shareholder's equity26.12M
Net tangible assets-128.05M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-203.84M
Capital expenditures (TTM)0.00
Free cash flow (TTM)-203.84M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-1055.60%
Return on Assets-51.49%
Return on Invested Capital-222.39%
Cash Return on Invested Capital-164.43%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open0.39
Daily high0.41
Daily low0.39
Daily Volume2.04M
All-time high29.17
1y analyst estimate1.63
Beta1.47
EPS (TTM)-1.57
Dividend per share-
Ex-div date-
Next earnings date2 Nov 2022

Downside potential

Loading...
Downside potential data
AKBAS&P500
Current price drop from All-time high-98.63%-12.18%
Highest price drop-98.91%-56.47%
Date of highest drop24 May 20229 Mar 2009
Avg drop from high-69.43%-11.38%
Avg time to new high354 days12 days
Max time to new high2061 days1805 days
COMPANY DETAILS
AKBA (Akebia Ther) company logo
Marketcap
73.41M
Marketcap category
Small-cap
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Employees
426
Investor relations
-
SEC filings
CEO
John P. Butler
Country
USA
City
Cambridge
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted six newly-hired employees options to purchase a...
September 2, 2022
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Offic...
September 1, 2022
Akebia Therapeutics Inc (NASDAQ: AKBA) announced initial findings from an investigator-sponsored study evaluating vadadustat for Acute Respiratory Distress Syndrome (ARDS) with COVID-19 and hypoxemia....
August 5, 2022
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 174.19% and 158.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
August 4, 2022
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the second quarte...
August 4, 2022
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced initial findings from an investigator-...
August 4, 2022
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results ...
July 26, 2022
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has executed an agreement to t...
June 30, 2022
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Offic...
June 3, 2022
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Offic...
May 19, 2022
Next page